KRYS

Krystal Biotech, Inc. NMS · KRYS

$328.26 -10.96 (-3.23%)

Pullback · -1.30σ

+ Compare Open in Sniper

Mkt cap $9.7B

P/E 44.0

Day $326.01 – $337.56

52wk $242.00 – $382.54

Avg vol 0.3M

Beta 0.50

Div yld —

Next earnings 2026-08-03

Quick read

Plain English

KRYS last traded at $328.26, down 3.2% on the day; that's in the middle part of its 52-week range ($242.00–$382.54). Right now it's dipped below its recent average — a spot where watchers often look for signs the dip is stabilizing.

The next scheduled earnings report (2026-08-03) is the biggest known catalyst on the calendar, and after the recent dip, watch whether the price stops making lower lows before assuming the worst is over.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

KC1 lower, -1.40 ATR from EMA21 — no notable pattern

Long —

score 20 · tech 20 / 80 · support 0 / 20

KC1 lower, -1.40 ATR from EMA21 · no notable pattern

· KC1 lower stretch — light dip
· Aligned with weak uptrend

How this grade was earned

total 20 pts

Cycle position 14

Market fit 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

score 9 · tech 9 / 80 · support 0 / 20

below KC1 upper, -1.40 ATR from EMA21 · no notable pattern

How this grade was earned

total 9 pts

Cycle position 6

Market fit 3

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

Our cash-flow model pegs fair value near $285.21 (fair range $40–$285); today's price sits 25% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Adequate. Model estimates only — do your own due diligence.

Intrinsic (DCF)

$285.21

Fair-value range

$39.60 – $285.21

Margin of safety

-25%

Verdict

Overvalued

Accounting quality Adequate

✓ More cash than debt
✓ Quick ratio 9.24 (antifragile)
✓ Current ratio 9.95 (antifragile)
✓ Debt/equity 0.09 (antifragile)

⚠ Inventory growing faster than revenue
⚠ Stock comp 14% of revenue (heavy dilution)

Price implies ~29% growth (vs trailing rev yoy). Model estimate — do your own due diligence.

Key statistics

All statistics →

KRYS is a $9.7 billion company, priced at 44× last year's earnings, and it moves more calmly than the market (beta 0.5).

Mkt cap $9.7B

P/E ttm 44.0

Fwd P/E 33.3

Beta 0.50

Day range $326.01 – $337.56

52w range $242.00 – $382.54

Avg vol 0.3M

RSI(2) 16.1

ROE 19.9%

Net mgn 53.9%

FCF mgn 33.0%

Debt/Eq 0.01

Div yld —

Sector Healthcare

Industry Biotechnology

Next earn 2026-08-03

52-week range · today's price

$242.00$382.54

More on KRYS

Options idea

See more →

CALL $330 2026-08-21

$35.00

PUT $330 2026-08-21

$15.50

Earnings

See more →

Last reported: 2026-05-04
EPS (act / est): 1.83 / 1.42
Surprise: +29.0%
Next report: 2026-08-03

About

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular comp…